ReviewFrontiers in pharmacology2026
Current therapeutic strategies and available research models for investigating hypertrophic scars.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abnormal scarring, such as hypertrophic and keloid scars, are a result of pathological skin wound healing, and can reduce quality of life through psychological factors, persistent pain, and reduced mobility. Under physiological conditions, wounds proceed sequentially through the hemostatic, inflammatory, proliferative, and remodeling phases of healing. However, dysregulated wound healing can overstimulate fibrotic activity, resulting in the development of hypertrophic or keloid scars. These scars present a significant clinical challenge, as hypertrophic scars develop in more than 70% of burn survivors with a 40%-94% incidence rate following surgery. While hypertrophic and keloid scars are a common health concern, treatment options are limited due to the complex nature of pathological scar development. Furthermore, the development of new therapeutics is complicated by limitations in research models mimicking scars
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.